MicroRNA‑133a downregulated EGFR expression in human non‑small cell lung cancer cells via AKT/ERK signaling

Guo,Nannan; Zhao,Yingnan; Zhang,Wen; Li,Shaojun; Li,Shanshan; Yu,Jianqi

doi:10.3892/ol.2018.9399

MicroRNA‑133a downregulated EGFR expression in human non‑small cell lung cancer cells via AKT/ERK signaling

Authors:
- Nannan Guo
- Yingnan Zhao
- Wen Zhang
- Shaojun Li
- Shanshan Li
- Jianqi Yu
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The First Affiliated Hospital of General Hospital of The Chinese People's Liberation Army, Beijing 100048, P.R. China, Xi Shan Clinic, 309th Hospital of PLA, Beijing 100091, P.R. China
Published online on: September 5, 2018 https://doi.org/10.3892/ol.2018.9399
Pages: 6045-6050

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) may serve important roles in the regulation of human non‑small cell lung cancer (NSCLC) cell growth and apoptosis. To the best of our knowledge, the present study was the first to explore the role of miRNA‑133a/epidermal growth factor receptor (EGFR) in regulating NSCLC cell growth and apoptosis via the AKT/extracellular signal‑regulated kinase (ERK) signaling pathway. It was determined that miRNA‑133a expression was lower in NSCLC tissue than in the adjacent mucosae. Additionally, EGFR expression in the NSCLC tissue was higher compared with in the adjacent mucosae. Furthermore, the upregulation of miRNA‑133a in NSCLC cells suppressed cell growth and induced apoptosis. Upregulating miRNA‑133a also increased caspase‑3 protein expression, while suppressing that of EGFR, phosphorylated (p)‑AKT and p‑ERK in NSCLC cells. Therefore, the results of the current study demonstrated that miRNA‑133a downregulates EGFR expression in NSCLC via the AKT/ERK signaling pathway. These findings provide insights into the function of miRNA‑133a in NSCLC, as well as into the molecular mechanisms underlying the miRNA‑133a‑mediated downregulation of the EGFR/AKT/ERK signaling pathway in NSCLC.

View Figures

View References

1	Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, Schild SE, Komaki R, Urbanic JJ, Timmerman RD and Choy H: A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage i peripheral non-small cell lung cancer: NRG oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 93:757–764. 2015. View Article : Google Scholar : PubMed/NCBI
2	Nie X, Cheng G, Ai B and Zhang S: The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer. Cancer Biomark. 13:433–440. 2013. View Article : Google Scholar : PubMed/NCBI
3	Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon G, et al: Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol. 31:4179–4187. 2013. View Article : Google Scholar : PubMed/NCBI
4	Wang R, Chen XF and Shu YQ: Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics. Am J Cancer Res. 5:32–51. 2014.PubMed/NCBI
5	Sin TK, Wang F, Meng F, Wong SC, Cho WC, Siu PM, Chan LW and Yung BY: Implications of MicroRNAs in the treatment of gefitinib-resistant non-small cell lung cancer. Int J Mol Sci. 17:2372016. View Article : Google Scholar : PubMed/NCBI
6	Chen F, Hou SK, Fan HJ and Liu YF: MiR-15a-16 represses Cripto and inhibits NSCLC cell progression. Mol Cell Biochem. 391:11–19. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wu N, Zhang C, Bai C, Han YP and Li Q: MiR-4782-3p inhibited non-small cell lung cancer growth via USP14. Cell Physiol Biochem. 33:457–467. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lin R, Chen L, Chen G, Hu C, Jiang S, Sevilla J, Wan Y, Sampson JH, Zhu B and Li QJ: Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Invest. 124:5352–5367. 2014. View Article : Google Scholar : PubMed/NCBI
9	Li N, Zhang F, Li S and Zhou S: Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell. Biochem Biophys Res Commun. 444:611–616. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wang X, Ling C, Bai Y and Zhao J: MicroRNA-206 is associated with invasion and metastasis of lung cancer. Anat Rec (Hoboken). 294:88–92. 2011. View Article : Google Scholar : PubMed/NCBI
11	Aghanoori MR, Mirzaei B and Tavallaei M: MiRNA molecular profiles in human medical conditions: Connecting lung cancer and lung development phenomena. Asian Pac J Cancer Prev. 15:9557–9565. 2014. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Dy GK, Hillman SL, Rowland KM Jr, Molina JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE and Adjei AA: North Central Cancer Treatment Group Study N0326: A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North central cancer treatment group study N0326. Cancer. 116:5686–5693. 2010. View Article : Google Scholar : PubMed/NCBI
14	Mita AC, Papadopoulos K, de Jonge MJ, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QS, Tolcher AW, Wood L, et al: Erlotinib ‘dosing-to-rash’: A phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer. 105:938–944. 2011. View Article : Google Scholar : PubMed/NCBI
15	Roa WH, Kim JO, Razzak R, Du H, Guo L, Singh R, Gazala S, Ghosh S, Wong E, Joy AA, et al: Sputum microRNA profiling: A novel approach for the early detection of non-small cell lung cancer. Clin Invest Med. 35:E2712012. View Article : Google Scholar : PubMed/NCBI
16	Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, et al: A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol. 22:104–109. 2011. View Article : Google Scholar : PubMed/NCBI
17	Karachaliou N, Rosell R, Morales-Espinosa D and Viteri S: Systemic treatment in EGFR-ALK NSCLC patients: Second line therapy and beyond. Expert Rev Anticancer Ther. 14:807–815. 2014. View Article : Google Scholar : PubMed/NCBI
18	Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA and Giaccone G: Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer. 118:209–214. 2006. View Article : Google Scholar : PubMed/NCBI
19	Raben D, Helfrich B and Bunn PA Jr: Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 59 2 Suppl:S27–S38. 2004. View Article : Google Scholar
20	Cui W, Zhang S, Shan C, Zhou L and Zhou Z: microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. FEBS J. 280:3962–3974. 2013. View Article : Google Scholar : PubMed/NCBI
21	Song X, Shi B, Huang K and Zhang W: miR-133a inhibits cervical cancer growth by targeting EGFR. Oncol Rep. 34:1573–1580. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zhen Y, Li D, Li W, Yao W, Wu A, Huang J, Gu H, Huang Y, Wang Y, Wu J, et al: Reduced PDCD4 expression promotes cell growth through PI3K/Akt signaling in non-small cell lung cancer. Oncol Res. 23:61–68. 2016. View Article : Google Scholar
23	Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B and Perez-Soler R: Targeting the PI3K/AKT/mTOR pathway: Potential for lung cancer treatment. Lung Cancer Manag. 3:67–75. 2014. View Article : Google Scholar : PubMed/NCBI
24	Dong M, Yang G, Liu H, Liu X, Lin S, Sun D and Wang Y: Aged black garlic extract inhibits HT29 colon cancer cell growth via the PI3K/Akt signaling pathway. Biomed Rep. 2:250–254. 2014. View Article : Google Scholar : PubMed/NCBI
25	Wang H, Wu C, Wan S, Zhang H, Zhou S and Liu G: Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway. Toxicology. 308:104–112. 2013. View Article : Google Scholar : PubMed/NCBI
26	Zinn RL, Gardner EE, Marchionni L, Murphy SC, Dobromilskaya I, Hann CL and Rudin CM: ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Mol Cancer Ther. 12:1131–1139. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zhao S, Wu J, Zheng F, Tang Q, Yang L, Li L, Wu W and Hann SS: β-elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKα signalling pathways in human lung cancer cells: the role of Sp1. J Cell Mol Med. 19:630–641. 2015. View Article : Google Scholar : PubMed/NCBI
28	Gao J, Zhao Y, Lv Y, Chen Y, Wei B, Tian J, Yang Z, Kong F, Pang J, Liu J and Shi H: Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells. Cancer Cell Int. 13:22013. View Article : Google Scholar : PubMed/NCBI